These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19838002)

  • 1. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine.
    Nishiyama K; Tsutamoto T; Yamaji M; Kawahara C; Yamamoto T; Fujii M; Horie M
    Circ J; 2009 Dec; 73(12):2270-5. PubMed ID: 19838002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure.
    Tsutamoto T; Sakai H; Nishiyama K; Tanaka T; Fujii M; Yamamoto T; Horie M
    Circ J; 2007 Dec; 71(12):1873-8. PubMed ID: 18037739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
    Wang F; Xu ZM; Wang L; Bian WY; Jia X; Duan B; Li W; Li YS
    Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):490-4. PubMed ID: 16080835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
    Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
    Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
    Azevedo ER; Kubo T; Mak S; Al-Hesayen A; Schofield A; Allan R; Kelly S; Newton GE; Floras JS; Parker JD
    Circulation; 2001 Oct; 104(18):2194-9. PubMed ID: 11684630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
    Kotlyar E; Keogh AM; Macdonald PS; Arnold RH; McCaffrey DJ; Glanville AR
    J Heart Lung Transplant; 2002 Dec; 21(12):1290-5. PubMed ID: 12490274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure.
    Tsutamoto T; Nishiyama K; Sakai H; Tanaka T; Fujii M; Yamamoto T; Yamaji M; Horie M
    Eur J Heart Fail; 2008 Dec; 10(12):1208-14. PubMed ID: 18977693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
    Li N; Li Y; Wang F; Jiang W; Huang J; Xu Z; Hua L; Hua C; Huang Y; Wu Y; Li F
    Clin Cardiol; 2007 Sep; 30(9):469-74. PubMed ID: 17803204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
    Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
    Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M; Nagai R; Izumi T; Matsuzaki M
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance.
    Cohen-Solal A; Jacobson AF; Piña IL
    ESC Heart Fail; 2017 Nov; 4(4):499-506. PubMed ID: 29154422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
    Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.
    Mori Y; Nishikawa Y; Kobayashi F; Hiramatsu K
    Int Heart J; 2013; 54(1):15-22. PubMed ID: 23428919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
    J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of sympathetic nervous system activity during administration of carvedilol in rats with dilated cardiomyopathy.
    Watanabe K; Abe Y; Sato S; Wahed M; Wen J; Narasimman G; Ma M; Ali F; Saito Y; Suresh P; Shirai K; Soga M; Nagai Y; Takahashi T; Hasegawa G; Naito M; Tachikawa H; Tanabe N; Kodama M; Aizawa Y; Yamaguchi K; Miyazaki M; Kakemi M
    J Cardiovasc Pharmacol; 2003 Dec; 42 Suppl 1():S93-7. PubMed ID: 14871037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
    Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
    Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM; Doughty R; Nicholls MG; Macmahon S; Ikram H; Sharpe N; Espiner EA; Frampton C; Yandle TG
    Circulation; 1999 Feb; 99(6):786-92. PubMed ID: 9989964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.